

INVITATION



Optimizing Treatment Strategies for Patients with Chronic Hepatitis B & C: Current and Future Therapies

- **Date:** 14 February 2009
- **Time:** 17:00 – 18:30
- **Venue:** Convention Hall A, Level 2, Old Wing
Hong Kong Convention and Exhibition Centre

Chairpersons

Dong Jin Suh, MD

*Professor of Hepatology
Department of Medicine
Asan Medical Center
University of Ulsan College of Medicine, Korea*

Deepak Amarapurkar, MD, DM

*Consultant Gastroenterologist
Department of Gastroenterology and Hepatology
Bombay Hospital & Medical Research Centre, India*

Speakers

John G McHutchison, MD

*Associate Director, Duke Clinical Research Institute
Director, GI/Hepatology Research Program
Professor of Medicine
Division of Gastroenterology
Duke University Medical Center, USA*

Geoffrey McCaughan, MD

*Head of Liver Immunobiology Program
Centenary Research Institute
AW Morrow Professor of Medicine
Director, AW Morrow GE/Liver Center
Director, Australian Liver Transplant Unit
Royal Prince Alfred Hospital
University of Sydney, Australia*

Ji-Dong Jia, MD

*Professor of Medicine
Director, Liver Research Center
Medical Director, Liver Transplant Program
Beijing Friendship Hospital
Capital Medical University, China*

PegIntron[®]
Peginterferon alfa-2b

**Schering-Plough Booth
Booth H, Hall 5B, Level 5**

Join this Expert Faculty for an Update on the Latest Developments in Hepatitis Management

Agenda

- 17:00 – 17:05 Welcome and Introduction
Dong Jin Suh, MD
- 17:05 – 17:35 Hepatitis C Initial Treatment: Maximizing Responses and Minimizing Relapse Rates with Current and Future Therapies
John G McHutchison, MD
- 17:35 – 18:00 Hepatitis C Retreatment: The Importance of Week 12 Response in Predicting PEG IFN- α Retreatment Success
Geoffrey McCaughan, MD
- 18:00 – 18:25 Hepatitis B Treatment Choice: Immune-Based PEG IFN- α or Direct Inhibitor?
Ji-Dong Jia, MD
- 18:25 – 18:30 Closing Remarks
Deepak Amarapurkar, MD, DM

Sponsored by  **Schering-Plough**

PegIntron[®]
Peginterferon alfa-2b

Disclaimer: PegIntron is not currently licensed in Hong Kong for use in hepatitis B

**You are Invited to Visit the Schering-Plough Booth
Booth H, Hall 5B, Level 5**